Merus (MRUS) Competitors $63.77 -0.83 (-1.28%) Closing price 04:00 PM EasternExtended Trading$63.72 -0.05 (-0.09%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. TEVA, GMAB, RDY, ASND, QGEN, MRNA, VTRS, BBIO, VRNA, and BPMCShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Moderna (MRNA), Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Qiagen Moderna Viatris BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Teva Pharmaceutical Industries (NYSE:TEVA) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Do analysts prefer TEVA or MRUS? Teva Pharmaceutical Industries presently has a consensus price target of $24.71, indicating a potential upside of 49.06%. Merus has a consensus price target of $88.50, indicating a potential upside of 38.78%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities analysts clearly believe Teva Pharmaceutical Industries is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Merus 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Do insiders & institutionals have more ownership in TEVA or MRUS? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 3.7% of Merus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, TEVA or MRUS? Teva Pharmaceutical Industries has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Is TEVA or MRUS more profitable? Teva Pharmaceutical Industries has a net margin of -0.95% compared to Merus' net margin of -685.64%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Merus -685.64%-50.28%-42.00% Does the media prefer TEVA or MRUS? In the previous week, Merus had 11 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 22 mentions for Merus and 11 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.09 beat Merus' score of 0.17 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merus 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Which has stronger earnings and valuation, TEVA or MRUS? Merus has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.63B1.14-$1.64B-$0.16-103.63Merus$56.23M85.78-$215.33M-$5.50-11.59 SummaryTeva Pharmaceutical Industries beats Merus on 9 of the 17 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.89B$3.00B$5.50B$9.70BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-11.5919.9630.3925.31Price / Sales85.78355.03447.52103.45Price / CashN/A40.7837.7258.50Price / Book5.737.658.306.01Net Income-$215.33M-$54.75M$3.26B$265.10M7 Day Performance-5.46%-0.15%0.91%1.13%1 Month Performance17.01%8.12%3.66%2.44%1 Year Performance23.23%24.55%46.29%27.98% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.8645 of 5 stars$63.77-1.3%$88.50+38.8%+27.3%$4.89B$56.23M-11.5937Positive NewsEarnings ReportAnalyst RevisionTEVATeva Pharmaceutical Industries3.3368 of 5 stars$15.70+2.1%$24.71+57.4%-5.8%$18.01B$16.54B-98.1336,830Positive NewsGMABGenmab A/S3.7382 of 5 stars$21.98+0.9%$37.80+72.0%-20.2%$14.10B$3.12B12.492,682Positive NewsEarnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories2.5393 of 5 stars$13.80-1.0%$16.95+22.9%-17.8%$11.52B$3.81B20.9027,811Positive NewsASNDAscendis Pharma A/S2.641 of 5 stars$184.15+5.5%$223.67+21.5%+54.3%$11.26B$393.54M-29.321,017News CoverageEarnings ReportAnalyst UpgradeQGENQiagen3.4798 of 5 stars$50.27+0.7%$49.40-1.7%+8.7%$11.17B$2.00B126.045,765Earnings ReportAnalyst DowngradeAnalyst RevisionMRNAModerna4.3649 of 5 stars$27.64+0.1%$45.61+65.0%-70.0%$10.69B$3.06B-3.675,800VTRSViatris1.791 of 5 stars$8.94+1.5%$10.40+16.3%-16.3%$10.49B$14.33B-2.8232,000News CoverageEarnings ReportAnalyst UpgradeBBIOBridgeBio Pharma4.4532 of 5 stars$47.75+0.8%$61.18+28.1%+97.5%$9.07B$127.42M-13.53400Trending NewsEarnings ReportAnalyst UpgradeInsider TradeVRNAVerona Pharma PLC American Depositary Share1.5523 of 5 stars$105.47+0.3%$109.00+3.3%+365.3%$8.55B$118.54M-52.7430Earnings ReportUpcoming EarningsBPMCBlueprint Medicines0.5772 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640 Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Qiagen Competitors Moderna Competitors Viatris Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Blueprint Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access